New gene therapy platform uses brain’s own fluid system to bypass blood-brain barrier

Researchers at the University of Rochester Medical Center have developed a gene therapy platform that exploits the brain's natural fluid transport network — the glymphatic system — to distribute engineered viral vectors broadly throughout brain tissue, offering a potential path around one of neurology's most stubborn obstacles: the blood-brain barrier.

The study, published July 8 in Nature Biotechnology, describes how specially modified adeno-associated virus serotype 5 (AAV5) vectors, delivered into the cisterna magna at the base of the brain and paired with hypertonic treatment to enhance cerebrospinal fluid uptake, achieved widespread transduction of human glial cells in chimeric mice while minimizing infection of peripheral organs.urmc.rochester+2

How It Works

The platform combines two innovations. First, the team used an in vivo selection process in human glial chimeric mice — animals whose brains contain human glial progenitor cells — to identify AAV5 capsid variants that preferentially infect human glia and their derived astrocytes and oligodendrocytes. Candidate capsids were filtered against visceral organs to eliminate vectors with systemic tropism.pubmed.ncbi.nlm.nih+1

Second, rather than delivering the vectors intravenously, the researchers injected them into cerebrospinal fluid and triggered systemic hypertonicity, which drove fluid into the brain's glymphatic channels. This approach distributed the AAVs throughout the brain parenchyma while largely bypassing the blood-brain barrier and reducing exposure to the liver, a common source of toxicity in conventional gene therapy.eurekalert+1

Therapeutic Implications

The researchers believe the platform could prove especially valuable for disorders of the brain's white matter, where glial cells play a central role. Potential applications include multiple sclerosis, Huntington's disease, age-related white matter loss, and rare childhood neurological conditions linked to glial dysfunction.urmc.rochester+1

> "Glymphatic delivery of capsid-modified AAV5s enables efficient transgene delivery to human glia throughout the entire adult mouse brain, with minimal off-target transduction," the authors wrote.nature+1

Remaining Hurdles

The work was conducted in mice, and translating the approach to human patients will require demonstrating safety and efficacy in larger animal models and eventually clinical trials. Still, by concentrating therapeutic vectors in the brain and away from other organs, the strategy addresses two persistent barriers to neurological gene therapy — limited distribution and systemic toxicity — in a single delivery framework.eurekalert+1